Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Treviso – page 59

920 clinical trials in Treviso, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Treviso at a glance
920
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

920 trials in Treviso

Open in trial search

Long-term Safety Study of KVD900 for Treating Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema Type I or II

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sebetralstat
  • Sponsor:Kalvista Pharmaceuticals Limited

Hepatic cirrhosis

Not recruiting

Study on the Effects of Human Serum Albumin on Survival in Patients with Severe Acute-On-Chronic Liver Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:Instituto Grifols S.A.

Study of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety and Effects of AZD5305 with Hormonal Agents for Patients with Metastatic Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Study of Tobemstomig with Platinum-Based Chemotherapy vs Pembrolizumab with Platinum-Based Chemotherapy for Untreated Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Not recruiting

Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Study on Rosnilimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab
  • Sponsor:Anaptysbio Inc.

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Treviso

What the registry says about research in the country

01 Hematologic Oncology

Innovative trials exploring treatments for Acute Myeloid Leukemia and Lymphomas, including studies on targeted therapies combined with standard chemotherapy. Research focuses on improving treatment outcomes for various blood cancers.

  • Gemtuzumab Ozogamicin for AML
  • Daratumumab for Plasmablastic Lymphoma
  • Follicular Lymphoma Treatment Optimization

Advanced therapeutic approaches aim to enhance minimal residual disease control and patient outcomes.

02 Gynecologic Oncology

Comprehensive research into ovarian cancer treatments, including studies of maintenance therapies and novel drug combinations. Investigations focus on both recurrent and newly diagnosed cases.

  • Olaparib Maintenance Therapy
  • Low-grade Serous Carcinoma Treatment
  • Cervical Cancer Prevention

Studies emphasize personalized treatment approaches based on specific genetic markers and disease characteristics.

03 Respiratory Medicine

Groundbreaking research in lung cancer and severe respiratory conditions, including targeted therapies for specific genetic mutations and innovative treatment combinations.

  • ALK-positive NSCLC Treatment
  • Small Cell Lung Cancer Therapy
  • Severe Asthma Management

Focus on developing personalized treatment strategies for various lung cancer subtypes and respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.